Screener
Gyre Therapeutics, Inc. GYRE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 94.3%-1.7pp | 95.2%-1.0pp | 95.5%-0.9pp | 95.6%-0.6pp | 96%-0.2pp | |
| Operating margin | -14%-18.7pp | -3.8%-14.1pp | 5.9%-9.4pp | 6.9%+79.4pp | 4.7%+65.3pp | |
| Net margin | -13.4%-15.1pp | -5.3%-12.6pp | 4.2%-7.3pp | 3.9%+88.4pp | 1.7%+78.7pp | |
| Returns | ||||||
| Return on equity | -16%-18.3pp | -7.5%-19.3pp | 8%— | 5.2%+272pp | 2.3%— | |
| Return on invested capital | -26.7%-32.7pp | -3.8%-23.1pp | 14.4%— | 9.5%— | 6.1%— | |
| Efficiency | ||||||
| Asset turnover | 0.7×-0.1× | 0.8×0.0× | 0.7×-0.2× | 0.8×-0.8× | 0.8×-0.9× | |
| Liquidity | ||||||
| Current ratio | 4.3×-1.1× | 4.6×+1.0× | 6.3×+3.0× | 6.2×+2.5× | 5.4×+2.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $1.07+4.0% | $1.11+66.0% | $0.61-2.1% | $0.98+59.3% | $1.03+74.7% | |
| Valuation | ||||||
| Market capitalization | $743.63M+11.2% | $636.46M-11.9% | $680.11M-34.5% | $677.57M-42.2% | $689.9M-32.4% | |
| Price / sales | 6.2×-0.1× | 5.3×-1.9× | 5.7×-4.1× | 6.1×-5.0× | 6.6×-2.6× | |
| Price / book | 6.6×-0.4× | 6.3×-4.3× | 10.9×-5.5× | 6.6×-11.9× | 7.5×-9.4× |
FAQ
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gyre Therapeutics, Inc. (GYRE) runs a 94.3% gross margin and a -14.0% operating margin, with a -13.4% net margin.
- Where do Gyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
